These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38849726)

  • 1. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
    BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
    BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.
    Perréard M; Florent R; Divoux J; Grellard JM; Lequesne J; Briand M; Clarisse B; Rousseau N; Lebreton E; Dubois B; Harter V; Lasne-Cardon A; Drouet J; Johnson A; Le Page AL; Bazille C; Jeanne C; Figeac M; Goardon N; Vaur D; Micault E; Humbert M; Thariat J; Babin E; Poulain L; Weiswald LB; Bastit V
    BMC Cancer; 2023 Mar; 23(1):223. PubMed ID: 36894916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
    Thorel L; Morice PM; Paysant H; Florent R; Babin G; Thomine C; Perréard M; Abeilard E; Giffard F; Brotin E; Denoyelle C; Villenet C; Sebda S; Briand M; Joly F; Dolivet E; Goux D; Blanc-Fournier C; Jeanne C; Villedieu M; Meryet-Figuiere M; Figeac M; Poulain L; Weiswald LB
    J Exp Clin Cancer Res; 2023 Oct; 42(1):260. PubMed ID: 37803448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response.
    Zhang F; Wang W; Long Y; Liu H; Cheng J; Guo L; Li R; Meng C; Yu S; Zhao Q; Lu S; Wang L; Wang H; Wen D
    Cancer Commun (Lond); 2018 Sep; 38(1):60. PubMed ID: 30257718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
    Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
    Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro drug testing using patient-derived ovarian cancer organoids.
    Chen LY; Chou YT; Liew PL; Chu LH; Wen KC; Lin SF; Weng YC; Wang HC; Su PH; Lai HC
    J Ovarian Res; 2024 Oct; 17(1):194. PubMed ID: 39358778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creating Matched In vivo/In vitro Patient-Derived Model Pairs of PDX and PDX-Derived Organoids for Cancer Pharmacology Research.
    Xu X; Shang L; Wang P; Zhou J; Ouyang X; Zheng M; Mao B; Zhang L; Chen B; Wang J; Chen J; Qian W; Guo S; Huang Y; Li QX
    J Vis Exp; 2021 May; (171):. PubMed ID: 34028430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    Tao M; Wu X
    J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model.
    Luo M; He Y; Xie B; Li S; Gan F; Zhang S; Luo P
    Pediatr Surg Int; 2021 Aug; 37(8):1031-1040. PubMed ID: 34031745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
    Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
    Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
    [No Abstract]   [Full Text] [Related]  

  • 13. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
    Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and clinical implementations of ovarian cancer mouse avatar models.
    Zayed AA; Mandrekar SJ; Haluska P
    Chin Clin Oncol; 2015 Sep; 4(3):30. PubMed ID: 26408297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.
    Dobbin ZC; Katre AA; Steg AD; Erickson BK; Shah MM; Alvarez RD; Conner MG; Schneider D; Chen D; Landen CN
    Oncotarget; 2014 Sep; 5(18):8750-64. PubMed ID: 25209969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
    Eckhardt BL; Gagliardi M; Iles L; Evans K; Ivan C; Liu X; Liu CG; Souza G; Rao A; Meric-Bernstam F; Ueno NT; Bartholomeusz GA
    PLoS One; 2018; 13(5):e0195932. PubMed ID: 29768500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
    Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
    Pépin D; Sosulski A; Zhang L; Wang D; Vathipadiekal V; Hendren K; Coletti CM; Yu A; Castro CM; Birrer MJ; Gao G; Donahoe PK
    Proc Natl Acad Sci U S A; 2015 Aug; 112(32):E4418-27. PubMed ID: 26216943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
    Ciucci A; Buttarelli M; Fagotti A; Scambia G; Gallo D
    Cell Mol Life Sci; 2022 Jun; 79(7):364. PubMed ID: 35705879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.